AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.545

-0.005-0.91%

Volume:1.13M

Turnover:620.06K

Market Cap:327.08M

PE:-12.33

High:0.560

Open:0.550

Low:0.540

Close:0.550

Loading ...

Overview Company News Filings

Change of Director's Interest Notice - SP-DXB.AX

Dimerix Receives First Development Milestone Payment From Japan Partner

MT Newswires Live

ASX ALERT-Dimerix receives 1st Development Milestone payment from FUSO-DXB.AX

Application for quotation of securities - DXB-DXB.AX

Application for quotation of securities - DXB-DXB.AX

Change of Director's Interest Notice - SP-DXB.AX

Investor Presentation-DXB.AX

Dimerix Meets Around 70% of Recruitment Target for Phase Three Kidney Disease Trial; Shares Down 5%

MT Newswires Live

ASX ALERT-ACTION3 Clinical Trial Milestone Recruitment Update-DXB.AX

Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment

MT Newswires Live

Dimerix Says Committee Noted No Safety Concerns in Phase Three Kidney Disease Candidate Clinical Trial Data

MT Newswires Live

Commercial, Development-Stage Biotechs Expected to See Little Impact from US Drug Pricing Order, Euroz Hartleys Says

MT Newswires Live

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus Therapeutics

Dimerix Ltd - Received Upfront Payment of US$30 Mln From Amicus Therapeutics

THOMSON REUTERS

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug

Guess which ASX All Ords stock is rocketing 58% on big US news

Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%

MT Newswires Live

BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.545,"timestamp":1752819120000,"preClose":0.55,"halted":0,"volume":1130521,"delay":0,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600142896,"eps":-0.044195,"marketStatus":"Market Closed","change":-0.005,"latestTime":"07-18 16:12:00 AEST","open":0.55,"high":0.56,"low":0.54,"amount":620062,"amplitude":0.036364,"askPrice":0.545,"askSize":49999,"bidPrice":0.54,"bidSize":22049,"shortable":3,"etf":0,"ttmEps":-0.044195,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1753056000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.55,"openAndCloseTimeList":[[1752796800000,1752818400000]],"volumeRatio":0.9787631814232637,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.9787631814232637,"shares":600142896,"dividePrice":0,"high":0.56,"amplitude":0.036364,"preClose":0.55,"low":0.54,"week52Low":0.3,"pbRate":"45.63","psRate":"443.27","week52High":0.785,"institutionHeld":0,"latestPrice":0.545,"committee":-0.387936,"eps":-0.044195,"divideRate":0,"volume":1130521,"delay":0,"ttmEps":-0.044195,"open":0.55,"prevYearClose":0.34,"prevWeekClose":0.53,"prevMonthClose":0.575,"prevQuarterClose":0.575,"fiveDayClose":0.53,"twentyDayClose":0.565,"sixtyDayClose":0.425},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2549307332","title":"Change of Director's Interest Notice - SP-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549307332","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549307332?lang=en_us&edition=fundamental","pubTime":"2025-07-07 13:46","pubTimestamp":1751867181,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nASX3mhT4p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250707:nASX2bzcGL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2547031511","title":"Dimerix Receives First Development Milestone Payment From Japan Partner","url":"https://stock-news.laohu8.com/highlight/detail?id=2547031511","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547031511?lang=en_us&edition=fundamental","pubTime":"2025-06-30 09:36","pubTimestamp":1751247381,"startTime":"0","endTime":"0","summary":"Dimerix  received the first development milestone payment of 400 million yen from Fuso Pharmaceutical Industries, the exclusive licensee of product candidate DMX-200 in Japan, according to a Monday filing with the Australian bourse.DMX-200 is being developed for the potential treatment of focal segmental glomerulosclerosis kidney disease, the filing said.The company may receive additional potential development and regulatory milestone payments of up to 3 billion yen and sales milestone payments of up to 6.8 billion yen, according to the filing.Shares rose nearly 2% in morning trade Monday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","DXB.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2547201038","title":"ASX ALERT-Dimerix receives 1st Development Milestone payment from FUSO-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547201038","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547201038?lang=en_us&edition=fundamental","pubTime":"2025-06-30 06:33","pubTimestamp":1751236392,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250629:nASXbRt5PL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250629:nASX5P7k59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","DXB.AU","BK7067","BK7501"],"gpt_icon":0},{"id":"2546793975","title":"Application for quotation of securities - DXB-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546793975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546793975?lang=en_us&edition=fundamental","pubTime":"2025-06-27 13:22","pubTimestamp":1751001773,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250627:nASX2vQ4cj","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nASX43Dyfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2545479484","title":"Application for quotation of securities - DXB-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545479484","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545479484?lang=en_us&edition=fundamental","pubTime":"2025-06-24 12:19","pubTimestamp":1750738763,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250624:nASX19Jlrj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250624:nASX4Thlzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2545466361","title":"Change of Director's Interest Notice - SP-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545466361","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545466361?lang=en_us&edition=fundamental","pubTime":"2025-06-23 11:27","pubTimestamp":1750649275,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASX2xpg44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX6KDb3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2544186485","title":"Investor Presentation-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2544186485","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544186485?lang=en_us&edition=fundamental","pubTime":"2025-06-19 06:22","pubTimestamp":1750285327,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250618:nASX8HRtSW","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nASXfs7XL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2543575774","title":"Dimerix Meets Around 70% of Recruitment Target for Phase Three Kidney Disease Trial; Shares Down 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543575774","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543575774?lang=en_us&edition=fundamental","pubTime":"2025-06-13 11:51","pubTimestamp":1749786682,"startTime":"0","endTime":"0","summary":"Dimerix  said that a total of 200 adult patients were randomized and dosed in its Action3 phase three clinical trial in patients with focal segmental glomerulosclerosis, representing around 70% of the total number of patients to be dosed in the two-year study, according to a Friday Australian bourse filing.The firm is targeting a total recruitment of around 286 adult patients. Full recruitment of patients into the trial is on track for the second half.The trial is seeking to evaluate the efficacy and safety of the firm's DMX200 treatment candidate in patients with focal segmental glomerulosclerosis, a kidney disease, the filing said. The participants are receiving a stable dose of an angiotensin II receptor blocker, and once this dose is stable, patients will be randomized to receive either DMX200 or a placebo.The trial is designed to capture evidence of kidney function and high levels of protein in the urine, which will be used as evidence to support marketing approval. The company ha","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7067","BK7508","DXB.AU"],"gpt_icon":0},{"id":"2543253295","title":"ASX ALERT-ACTION3 Clinical Trial Milestone Recruitment Update-DXB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2543253295","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543253295?lang=en_us&edition=fundamental","pubTime":"2025-06-13 06:58","pubTimestamp":1749769137,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250612:nASXVDBWN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nASX5v8Pjb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2539905282","title":"Dimerix Confirms First Japan Clinical Trial Site Open for Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2539905282","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539905282?lang=en_us&edition=fundamental","pubTime":"2025-05-30 09:00","pubTimestamp":1748566849,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.The company anticipates receiving the milestone payment from Fuso within 30 days.Shares rose nearly 2% in morning trade Friday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2537964022","title":"Dimerix Says Committee Noted No Safety Concerns in Phase Three Kidney Disease Candidate Clinical Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2537964022","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537964022?lang=en_us&edition=fundamental","pubTime":"2025-05-22 10:54","pubTimestamp":1747882467,"startTime":"0","endTime":"0","summary":"Dimerix  confirmed that the independent data monitoring committee concluded a sixth review of the ACTION3 phase three clinical trial safety data, noting no safety concerns and recommending that the clinical trial continue as planned, according to a Thursday Australian bourse filing.The next scheduled meeting for the committee is set to be in the fourth quarter, the filing said.The phase three study is a multi-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker.The trial is designed to capture evidence of proteinuria and kidney function during the testing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DXB.AU","BK7501","BK7067","BK7508"],"gpt_icon":0},{"id":"2535060550","title":"Commercial, Development-Stage Biotechs Expected to See Little Impact from US Drug Pricing Order, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2535060550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535060550?lang=en_us&edition=fundamental","pubTime":"2025-05-14 13:35","pubTimestamp":1747200923,"startTime":"0","endTime":"0","summary":"Commercial and development-stage biotechnology companies are expected to face minimal to no impact from the recent US executive order aimed at lowering drug prices, according to a Wednesday note by Eu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SSI","BK7067","AGN.AU","BOT.AU","CYP.AU","BK7502","DXB.AU","BK7096","BK7508","SNT.AU","BK7501"],"gpt_icon":0},{"id":"2533517776","title":"Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2533517776","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533517776?lang=en_us&edition=fundamental","pubTime":"2025-05-06 10:36","pubTimestamp":1746499006,"startTime":"0","endTime":"0","summary":"In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is no course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,144.3 points. Four ASX shares that are","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/06/why-dimerix-evolution-mining-inghams-and-nextdc-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK4213","EPM","ING.AU","BK7501","BK7104","BK7505","BK7508","BK7506","EVN.AU","BK7043","XJO.AU","BK7141","BK7503","NXT.AU","DXB.AU"],"gpt_icon":0},{"id":"2533594171","title":"BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2533594171","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533594171?lang=en_us&edition=fundamental","pubTime":"2025-05-06 09:32","pubTimestamp":1746495143,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus TherapeuticsMay 6 (Reuters) - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF US$30 MILLION FROM AMICUS THERAPEUTICSFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RD226:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","DXB.AU","BK7508"],"gpt_icon":0},{"id":"2533623365","title":"Dimerix Ltd -  Received Upfront Payment of US$30 Mln From Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533623365?lang=en_us&edition=fundamental","pubTime":"2025-05-06 06:27","pubTimestamp":1746484057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD226:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2532389310","title":"Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532389310","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532389310?lang=en_us&edition=fundamental","pubTime":"2025-05-02 11:33","pubTimestamp":1746156793,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.9% to 8,218.5 points. Four ASX shares that are rising more than mos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/02/why-boss-energy-capstone-dimerix-and-platinum-shares-are-storming-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7508","DXB.AU","PTM.AU","LU2065171311.SGD","BK7110","FOLD","LU2065171402.SGD","XJO.AU","BOE.AU","BK7062","CSC.AU","BK4139","LU2065170008.USD","BK7083","BK7501","LU2065169927.USD"],"gpt_icon":0},{"id":"2532049548","title":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2532049548","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532049548?lang=en_us&edition=fundamental","pubTime":"2025-05-01 12:23","pubTimestamp":1746073390,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020** Stock marks biggest intraday pct gain since October 5, 2023** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg** Last up 50%, DXB more than doubles YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nL4N3R909Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","DXB.AU","BK4139","LU2065171311.SGD","LU2065169927.USD","BK7508","LU2065170008.USD","BK7067","FOLD","BK7501"],"gpt_icon":0},{"id":"2532108840","title":"Guess which ASX All Ords stock is rocketing 58% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2532108840","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532108840?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:13","pubTimestamp":1746062011,"startTime":"0","endTime":"0","summary":"The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher. In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news. Which ASX All Ords stock is rocketing?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/01/guess-which-asx-all-ords-stock-is-rocketing-58-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2065171311.SGD","LU2065171402.SGD","BK7508","LU2065170008.USD","BK4139","FSGS","LU2065169927.USD","BK7067","FOLD","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","DMX","BK7501","FSGS"],"gpt_icon":0},{"id":"2532501587","title":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532501587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532501587?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:15","pubTimestamp":1746054919,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United StatesMay 1  - Dimerix Ltd DXB.AX:DIMERIX AND AMICUS THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR DMX-200 IN UNITED STATESDIMERIX TO RECEIVE US$30 MILLION UPFRONT PAYMENTDIMERIX TO RECEIVE UP TO US$560 MILLION FOR SUCCESS-BASED MILESTONE PAYMENTSFurther company coverage: DXB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","BK7067","DXB.AU","LU2065170008.USD","FOLD","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[]}}